Posted by Michael Wonder on 31 Oct 2016
TGA approves yet another use for Humira (adalimumab)
31 October 2016 - AbbVie clocks up another indication for its TNF-alfa inhibitor.
Humira is now indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid sparing, or in whom corticosteroid treatment is inappropriate.
The TGA approved the use of adalimumab by patients with uveitis on 25 October 2016.
